BioCorRx Inc
OTC:BICX
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
BioCorRx Inc
OTC:BICX
|
6.9m USD |
Loading...
|
|
| US |
|
HCA Healthcare Inc
NYSE:HCA
|
121.2B USD |
Loading...
|
|
| SA |
|
Dr Sulaiman Al-Habib Medical Services Group Co
SAU:4013
|
98B SAR |
Loading...
|
|
| ZA |
N
|
Netcare Ltd
JSE:NTC
|
23.2B ZAR |
Loading...
|
|
| US |
|
Tenet Healthcare Corp
NYSE:THC
|
20.5B USD |
Loading...
|
|
| MY |
I
|
IHH Healthcare Bhd
KLSE:IHH
|
79.7B MYR |
Loading...
|
|
| ZA |
L
|
Life Healthcare Group Holdings Ltd
JSE:LHC
|
17.6B ZAR |
Loading...
|
|
| BR |
|
Rede D'Or Sao Luiz SA
BOVESPA:RDOR3
|
90B BRL |
Loading...
|
|
| CN |
A
|
Aier Eye Hospital Group Co Ltd
SZSE:300015
|
98.8B CNY |
Loading...
|
|
| US |
|
Universal Health Services Inc
NYSE:UHS
|
12.6B USD |
Loading...
|
|
| IN |
|
Apollo Hospitals Enterprise Ltd
NSE:APOLLOHOSP
|
1.1T INR |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
BioCorRx Inc
Glance View
BioCorRx, Inc. engages in the provision of alcoholism and opioid addiction treatment. The company is headquartered in Anaheim, California. The company went IPO on 2010-08-31. The firm's BioCorRx Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application. The company is also engaged in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Its products include BICX101 and BICX104. Its lead candidate, BICX101, is a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. The company is also developing an implantable naltrexone treatment, BICX104, a long-acting naltrexone implant that can last several months for the treatment of opioid dependence and alcohol use disorders. Its subsidiary is BioCorRx Pharmaceuticals, Inc.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for BioCorRx Inc is 100%, which is above its 3-year median of 74.9%.
Over the last 3 years, BioCorRx Inc’s Gross Margin has increased from 83.3% to 100%. During this period, it reached a low of 44.7% on Sep 30, 2024 and a high of 100% on Jul 30, 2025.
